Incyte Corp. leveraged its positive cash flow to invest in its immuno-oncology (I-O) future through a license and collaboration agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop and commercialize anti-PD-1 monoclonal antibody SHR-1210.